摘要:
Clostridium difficile is one of the most common causes of health-care acquired diarrhoea, resulting in a spectrum of disease from mild diarrhoea to life-threatening illness. Particular human Lactobacillus strains, including Lactobacillus gasseri APC678, are described as useful therapeutic agents to target C. difficile colonisation or infection.
摘要:
Isolated bacteria are described that are characterised by being culturable, derived from a human neonatal gastrointestinal tract, and having the ability to produce gamma-aminobutyric acid. Also described is the use of the GABA-producing bacteria in the treatment or regulation of cardiovascular function, mood disturbance, anxiety, stress, pain and proliferative disorders.
摘要:
Isolated bacteria are described that are characterised by being culturable, derived from a human neonatal gastrointestinal tract, and having the ability to produce gamma-aminobutyric acid. Also described is the use of the GABA-producing bacteria in the treatment or regulation of cardiovascular function, mood disturbance, anxiety, stress, pain and proliferative disorders.
摘要:
The invention provides a probiotic composition to alleviate Salmonella infection in farm animals. The composition may comprise at least one of Lactobacillus murinus, Lactobacillus pentosus, Lactobacillus salivarius sub-species salivarius, and Pediococcus pentosaceus. The composition maybe formulated as an animal feedstuff, or as a pharmaceutical composition.
摘要:
The present invention relates to a new bacteriocin, to microbial strains which can produce it and to uses of the bacteriocin and the strains. The bacteriocin is effective against Clostridium difficile and Listeria monocytogenes amongst other organisms.
摘要:
The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.
摘要:
The invention relates to a variant nisin peptide, wherein the variant nisin peptide is a modified variant of wild-type nisin, wherein the modification comprises or consists of an amino acid residue modification selected from: i) M17Q or M17A; ii) T2L; and iii) one set of modified hinge residues selected from a) N20H and M21T, b) N20V, M21G, and K22A, c) N20V, M21G, and K22V or d) N20V, M21G, and K22T; or v) combinations of modifications i), ii), and iii), and related medical uses and products comprising such nisin peptides.
摘要:
An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide having potent antibacterial activity against Lactobacillus delbrueckii subspecies bulgaricus, Listeria and Staphylococcus aureus.
摘要翻译:描述了对单核细胞增生利斯特氏菌和金黄色葡萄球菌具有有效抗菌活性的抗微生物肽。 还描述了以保藏号NCIMB 41840保藏在National Collection of Industrial and Marine Bacteria的分离的唾液乳杆菌DPC6502菌株及其变体,其中分离的细菌及其变体表达对德氏乳杆菌具有强抗菌活性的抗微生物肽 亚种保加利亚,李斯特菌和金黄色葡萄球菌。